Current place of vasopressin analogues in the treatment of septic shock

Current Infectious Disease Reports

Volumn 10, Issue 5, 2008, Pages 362-367

  Ertmer, Christian ^a   Rehberg, Sebastian ^b   Morelli, Andrea ^b   Westphal, Martin ^b  

^a UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ARGIPRESSIN; CORTICOSTEROID; DOBUTAMINE; HYPERTENSIVE FACTOR; NORADRENALIN; TERLIPRESSIN;

ANTIDIURESIS; BILIRUBIN BLOOD LEVEL; BOLUS INJECTION; CAPILLARY LEAK SYNDROME; CARDIOVASCULAR FUNCTION; CLINICAL TRIAL; CONTINUOUS INFUSION; CREATININE BLOOD LEVEL; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG DOSE TITRATION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MEGADOSE; ENDOTOXEMIA; HEART OUTPUT; HUMAN; HYPOTENSION; LOW DRUG DOSE; MEAN ARTERIAL PRESSURE; MICROCIRCULATION; MORTALITY; NONHUMAN; OPTIMAL DRUG DOSE; OXYGEN TRANSPORT; REPEATED DRUG DOSE; REVIEW; SEPTIC SHOCK; SIDE EFFECT; SKIN NECROSIS; VASCULAR RESISTANCE; VASODILATATION;

EID: 63249121681     PISSN: 15233847     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11908-008-0059-y     Document Type: Review

References (45)

1. Acher R: Structure evolution and processing adaptation of neurohypophysial hormone-neurophysin precursors. Prog Clin Biol Res 1990, 342:1-9.
2. du Vigneaud V, Lawler HC, Popenoe EA: Enzymic cleavage of glycinamide from vasopressin and a proposed structure for this pressorantidiuretic hormone of the posterior pituitary. J Am Chem Soc 1953, 75:4880-4881.
3. Dunser MW, Westphal M: Arginine vasopressin in vasodilatory shock: effects on metabolism and beyond. Curr Opin Anesthesiol 2008, 21:122-127.
4. Smith WW: Pitressin toxicity in diabetes insipidus, and the therapeutic superiority of the nasal route for replacement therapy; report of a case. Ohio Med 1957, 53:1277-1279.
5. Chojkier M, Groszmann RJ, Atterbury CE, et al.: A controlled comparison of continuous intraarterial and intravenous infusions of vasopressin in hemorrhage from esophageal varices. Gastroenterology 1979, 77:540-546.
6. Andersson KE, Arner B: Effects of DDAVP, a synthetic analogue of vasopressin, in patients with cranial diabetes insipidus. Acta Med Scand 1972, 192:21-27.
7. Chiu KW, Sheen IS, Liaw YF: A controlled study of glypressin versus vasopressin in the control of bleeding from oesophageal varices. J Gastroenterol Hepatol 1990, 5:549-553.
8. Holmes CL, Patel BM, Russell JA, Walley KR: Physiology of vasopressin relevant to management of septic shock. Chest 2001, 120:989-1002.
9. Lange M, Ertmer C, Westphal M: Vasopressin vs. terlipressin in the treatment of cardiovascular failure in sepsis. Intensive Care Med 2008, 34:821-832.
10. Sharshar T, Blanchard A, Paillard M, et al.: Circulating vasopressin levels in septic shock. Crit Care Med 2003, 31:1752-1758.
11. Forsling ML, Aziz LA, Miller M, et al.: Conversion of triglycylvasopressin to lysine-vasopressin in man. J Endocrinol 1980, 85:237-244.
12. Nilsson G, Lindblom P, Ohlin M, et al.: Pharmacokinetics of terlipressin after single i.v. doses to healthy volunteers. Drugs Exp Clin Res 1990, 16:307-314.
13. Asfar P, Hauser B, Ivanyi Z, et al.: Low-dose terlipressin during long-term hyperdynamic porcine endotoxemia: Effects on hepatosplanchnic perfusion, oxygen exchange, and metabolism. Crit Care Med 2005, 33:373-380.
14. Lange M, Morelli A, Ertmer C, et al.: Continuous versus bolus infusion of terlipressin in ovine endotoxemia. Shock 2007, 28:623-629.
15. Westphal M, Stubbe H, Sielenkamper AW, et al.: Terlipressin dose response in healthy and endotoxemic sheep: Impact on cardiopulmonary performance and global oxygen transport. Intensive Care Med 2003, 29:301-308.
16. Jolley DH, De Keulenaer BL, Potter A, Stephens DP: Terlipressin infusion in catecholamine-resistant shock. Anaesth Intensive Care 2003, 31:560-564.
17. Morelli A, Ertmer C, Lange M, Westphal M: Continuous terlipressin infusion in patients with septic shock: Less may be best, and the earlier the better? Intensive Care Med 2007, 33:1669-1670.
18. Umgelter A, Reindl W, Schmid RM, Huber W: Continuous terlipressin infusion in patients with persistent septic shock and cirrhosis of the liver. Intensive Care Med 2008, 34:390-391.
19. Landry DW, Levin HR, Gallant EM, et al.: Vasopressin deficiency contributes to the vasodilation of septic shock. Circulation 1997, 95:1122-1125.
20. Sharshar T, Carlier R, Blanchard A, et al.: Depletion of neurohypophyseal content of vasopressin in septic shock. Crit Care Med 2002, 30:497-500.
21. Landry DW, Levin HR, Gallant EM, et al.: Vasopressin pressor hypersensitivity in vasodilatory septic shock. Crit Care Med 1997, 25:1279-1282.
22. Malay MB, Ashton RC Jr, Landry DW, Townsend RN: Low-dose vasopressin in the treatment of vasodilatory septic shock. J Trauma 1999, 47:699-703; discussion 703-695.
23. Patel BM, Chittock DR, Russell JA, Walley KR: Beneficial effects of short-term vasopressin infusion during severe septic shock. Anesthesiology 2002, 96:576-582.
24. Tsuneyoshi I, Yamada H, Kakihana Y, et al.: Hemodynamic and metabolic effects of low-dose vasopressin infusions in vasodilatory septic shock. Crit Care Med 2001, 29:487-493.
25. Klinzing S, Simon M, Reinhart K, et al.: High-dose vasopressin is not superior to norepinephrine in septic shock. Crit Care Med 2003, 31:2646-2650.
26. Lauzier F, Levy B, Lamarre P, Lesur O: Vasopressin or norepinephrine in early hyperdynamic septic shock: A randomized clinical trial. Intensive Care Med 2006, 32:1782-1789.
27. Dunser MW, Mayr AJ, Ulmer H, et al.: Arginine vasopressin in advanced vasodilatory shock: A prospective, randomized, controlled study. Circulation 2003, 107:2313-2319.
28. Dunser MW, Mayr AJ, Ulmer H, et al.: The effects of vasopressin on systemic hemodynamics in catecholamine-resistant septic and postcardiotomy shock: A retrospective analysis. Anesth Analg 2001, 93:7-13.
29. Westphal M, Stubbe H, Sielenkamper AW, et al.: Effects of titrated arginine vasopressin on hemodynamic variables and oxygen transport in healthy and endotoxemic sheep. Crit Care Med 2003, 31:1502-1508.
30. van Haren FM, Rozendaal FW, van der Hoeven JG: The effect of vasopressin on gastric perfusion in catecholamine-dependent patients in septic shock. Chest 2003, 124:2256-2260.
31. Westphal M, Freise H, Kehrel BE, et al.: Arginine vasopressin compromises gut mucosal microcirculation in septic rats. Crit Care Med 2004, 32:194-200.
32. Asfar P, Pierrot M, Veal N, et al.: Low-dose terlipressin improves systemic and splanchnic hemodynamics in fluid-challenged endotoxic rats. Crit Care Med 2003, 31:215-220.
33. Albanese J, Leone M, Delmas A, Martin C: Terlipressin or norepinephrine in hyperdynamic septic shock: A prospective, randomized study. Crit Care Med 2005, 33:1897-1902.
34. Morelli A, Rocco M, Conti G, et al.: Effects of terlipressin on systemic and regional haemodynamics in catecholamine-treated hyperkinetic septic shock. Intensive Care Med 2004, 30:597-604.
35. O'Brien A, Clapp L, Singer M: Terlipressin for norepinephrine-resistant septic shock. Lancet 2002, 359:1209-1210.
36. Leone M, Albanese J, Delmas A, et al.: Terlipressin in catecholamine-resistant septic shock patients. Shock 2004, 22:314-319.
37. Russell JA, Walley KR, Singer J, et al.: Vasopressin versus norepinephrine infusion in patients with septic shock. N Engl J Med 2008, 358:877-887.
38. Bagshaw SM, George C, Dinu I, Bellomo R: A multi-centre evaluation of the RIFLE criteria for early acute kidney injury in critically ill patients. Nephrol Dial Transplant 2008, 23:1203-1210.
39. Dellinger RP, Levy MM, Carlet JM, et al.: Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008. Intensive Care Med 2008 34:17-60.
40. Luckner G, Mayr VD, Jochberger S, et al.: Comparison of two dose regimens of arginine vasopressin in advanced vasodilatory shock. Crit Care Med 2007, 35:2280-2285.
41. Morelli A, Ertmer C, Lange M, et al.: Effects of short-term simultaneous infusion of dobutamine and terlipressin in patients with septic shock: the DOBUPRESS study. Br J Anaesth 2008, 100:494-503.
42. Rehberg S, Ertmer C, Lange M, et al.: Vasopressin and terlipressin as first-line therapy in fulminant ovine septic shock [abstract]. Crit Care 2008, 12:P405.
43. Traber D: Selective V1a receptor agonists in experimental septic shock [abstract]. Crit Care 2007, 11:P51.
44. Laporte R, Russell J, Landry D, Riviere P: Selective V1a receptor agonist FE 202158 reverses platelet-activating factor-induced hypotension, vascular leak, impaired tissue perfusion, and mortality in rats [abstract]. Crit Care 2008, 12:P407.
45. Morelli A, Ertmer C, Lange M, et al.: Continuous terlipressin versus vasopressin infusion in septic shock: The TERLIVAP study [abstract]. Crit Care 2008, 12:P403.